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Although fecal occult-blood testing is the only available noninvasive screening method
that reduces the risk of death from colorectal cancer, it has limited sensitivity. We com-
pared an approach that identifies abnormal DNA in stool samples with the Hemoccult II




Eligible subjects submitted one stool specimen for DNA analysis, underwent standard
Hemoccult II testing, and then underwent colonoscopy. Of 5486 subjects enrolled, 4404
completed all aspects of the study. A subgroup of 2507 subjects was analyzed, including
all those with a diagnosis of invasive adenocarcinoma or advanced adenoma plus ran-





The fecal DNA panel detected 16 of 31 invasive cancers, whereas Hemoccult II iden-
tified 4 of 31 (51.6 percent vs. 12.9 percent, P=0.003). The DNA panel detected 29 of
71 invasive cancers plus adenomas with high-grade dysplasia, whereas Hemoccult II
identified 10 of 71 (40.8 percent vs. 14.1 percent, P<0.001). Among 418 subjects with
advanced neoplasia (defined as a tubular adenoma at least 1 cm in diameter, a polyp
with a villous histologic appearance, a polyp with high-grade dysplasia, or cancer), the
DNA panel was positive in 76 (18.2 percent), whereas Hemoccult II was positive in 45
(10.8 percent). Specificity in subjects with negative findings on colonoscopy was 94.4




Although the majority of neoplastic lesions identified by colonoscopy were not detect-
ed by either noninvasive test, the multitarget analysis of fecal DNA detected a greater
proportion of important colorectal neoplasia than did Hemoccult II without compro-
mising specificity.
abstract
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fecal dna for colorectal-cancer screening
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olorectal cancer is the second
 





 Despite recommendations en-
dorsing screening, less than 40 percent of people





 Guaiac-based chemical detection of
fecal occult blood is the only noninvasive screening










 when used programmatically. However,
the sensitivity of fecal occult-blood testing for colo-
rectal cancer and especially for colorectal adeno-
mas is low because neoplasms may not bleed and





ity of a simple, noninvasive test that detects tumor-
specific products with reasonable sensitivity and
specificity might overcome barriers to screening
among patients who are not willing to undergo
more sensitive but more invasive tests, such as co-
lonoscopy.
The molecular genetics of colorectal cancer pro-




Eighty-five percent of colorectal cancers result from
chromosomal instability, with mutations progres-


















 The other 15 percent arise
from a loss of genes involved in DNA-mismatch re-





lorectal cancer may also be detectable through the





Previous studies using fecal-based DNA testing
have reported a sensitivity of 62 to 91 percent for
cancer and 27 to 82 percent for advanced adeno-
mas, with a specificity of 93 to 96 percent in persons





er, those studies assessed persons with advanced,
symptomatic lesions. We made a head-to-head com-
parison of a fecal-based, multitarget DNA panel
with Hemoccult II in asymptomatic adults, 50 years
of age or older, who were at average risk for colo-
rectal cancer. The primary objective was to compare
detection rates for colorectal cancer and for colorec-
tal cancer plus adenomas with high-grade dysplasia.
 
study design and rationale
 
The rationale for the study was based on screen-
ing guidelines indicating that newer screening tests
need not demonstrate a reduction in cost-specific
mortality but should be at least as sensitive, specific,





 Hemoccult II (Beckman Coulter, for-
merly SmithKline Diagnostics) was chosen for the
comparison with the DNA panel because it is the
only fecal occult-blood test proven to reduce the in-
cidence and risk of death from colorectal cancer





study was designed by the authors, with advice from
national experts on colorectal cancer, cancer screen-




The study was conducted at 81 sites, including
private-practice and university-based settings. Sub-
jects were enrolled between August 2001 and March
2003. All subjects first provided a fecal sample for
DNA testing and then completed three Hemoccult II
cards before undergoing screening colonoscopy.
All tests were conducted in a blinded fashion. Stool
samples were analyzed for DNA abnormalities with-
out knowledge of Hemoccult II or colonoscopy re-
sults; colonoscopy was performed without knowl-
edge of the results of fecal DNA testing. Since
Hemoccult II testing was conducted at the study
sites, the results were potentially available to the
colonoscopists. A clinical research organization
(Parexel) received the results of Hemoccult II tests
and colonoscopy directly from the clinical sites and
received the results of fecal DNA analyses from the
clinical laboratory (Exact Sciences).
Parexel conducted the data analyses according
to a prespecified plan and provided the results to
the investigators after completion of the study. Only
Parexel had access to the data until the blinding
was removed, at which time the information was
shared with the authors. The authors wrote the ar-
ticle; Exact Sciences guaranteed the first author the
right to publish the results of the study regardless
of the outcome. Parexel, CareStat (the company that
provided biostatistical support), and the authors
each independently vouch for the veracity of the




The target population consisted of asymptomatic
persons at average risk for colorectal cancer. The
appropriate institutional review board at each site
approved the study. Written informed consent was
obtained from all participants. Study sites recruit-




*See NAPS document no. PC0001 for 112 pages of supplementary
material regarding the study protocol. To order, contact NAPS, c/o
Burrows Systems, P.O. Box 3976, New Hyde Park, NY 11040.
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tivities to enhance the public’s awareness of colo-
rectal cancer and the availability of screening. The
costs of colonoscopy were not covered by the study;
Hemoccult II and fecal DNA testing was provided
without charge. Participants were compensated in
a manner approved by each site’s institutional re-
view board.
All participants were at least 50 years old. En-
rollment was stratified according to age, with a min-
imum of three quarters of subjects 65 years of age
or older. Exclusion criteria included gastrointesti-
nal bleeding within the preceding month, a change
in bowel habits or a recent onset of abdominal pain,
previous colorectal cancer or polyps, prior resec-
tion of any part of the colon, iron-deficiency ane-
mia, or other coexisting visceral cancer. Persons who
had undergone colonoscopy, sigmoidoscopy, or
double-contrast barium enema within the preced-
ing 10 years or who had had a positive fecal occult-
blood test within the preceding 6 months were ex-
cluded, as were those with inflammatory bowel
disease, familial adenomatous polyposis or hered-
itary nonpolyposis colon cancer, more than one first-
degree relative with colorectal cancer, or any first-
degree relative with colorectal cancer before the age
of 50 years. Persons unwilling or unable to under-




Subjects were given detailed instructions for stool
collection; no dietary or medication modifications
were required. Specimens were shipped directly
to the clinical laboratory in a bar-coded container,
chilled to between 0 and 4°C. Specimens were re-
quired to arrive within 72 hours after collection; a
minimal 30-g sample was required. If a sample
failed to meet these requirements, another sample
was sought before colonoscopy was performed.
Samples were stored at –80°C until analysis.
Subjects were given three Hemoccult II cards
and instructions regarding dietary and medication





 Cards were returned to physicians’
offices for non-rehydrated analysis by the physician
or a designee, consistent with the manufacturer’s
instructions and current guidelines. If all three cards
(six panels) were not completed, additional cards
were provided.
Colonoscopy was performed with the prepara-
tion and sedation customarily used at each site. The
colonoscopist documented the extent of the colon
that was visualized and the quality of the bowel
preparation. Adequate colonoscopy required visu-
alization of the cecum and a minimum of 90 per-
cent of the mucosa. The size and location of any
lesions were recorded. Biopsy and surgical resec-
tion specimens were examined histopathologi-
cally at each site; no centralized pathological review
was performed.
Subjects could be evaluated only if the speci-
men for fecal DNA analysis was adequate, all six
Hemoccult II panels had been completed, and co-
lonoscopy was adequate. Subjects were classified
according to the most advanced lesion identified.
Advanced adenoma was defined as any lesion con-
taining high-grade dysplasia, a polyp containing
clinically significant villous architecture, or a tubu-
lar adenoma that was at least 1 cm in diameter. Mi-
nor polyps included tubular adenomas less than
1 cm in diameter and hyperplastic polyps.
Parexel provided the clinical laboratory with a
coded list of stool specimens to be analyzed for
DNA abnormalities on the basis of colonoscopy
and pathological reports. The prespecified analytic
plan was designed to maximize the study’s efficien-
cy without compromising measures of sensitivi-
ty, specificity, and adherence to the protocol. DNA
analysis was performed on stool samples from all
subjects with an invasive cancer or advanced ade-
noma who could be evaluated and on randomly se-
lected subgroups of 600 subjects with minor pol-
yps and 1400 subjects with no polyps; these groups




All samples analyzed for fecal DNA were processed
in a single laboratory. The fecal DNA panel con-












 gene; the microsatellite-
instability marker BAT-26; and a marker of long
DNA thought to reflect disordered apoptosis of









 and is shown in Figure 1. Laboratory
handling of all samples was fully automated, and
quantitative analysis of the area under the curve, a
measure of signal intensity of the labeled nucle-
otides, was compared with that for control DNA
fragments with a known mutation. Each marker
was assessed independently; a positive result for any
component of the panel constituted a positive fecal
DNA test. Laboratory technicians were unaware of
both the clinical data associated with each sample
and the sampling protocol.
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
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Figure 1. Approach to Extraction and Analysis of Fecal DNA.
 
Stool samples were thawed at room temperature and homogenized. Aliquots (each equivalent to 4 g of stool) were centri-
fuged to remove particulate matter. Crude DNA was precipitated and resuspended. Sequence-specific DNA fragments were 
then purified from the total nucleic acid preparations by performing oligonucleotide-based hybrid “captures.” To analyze sam-
ples directly for the presence of long DNA, the purified DNA was amplified in a real-time polymerase chain reaction (PCR), tar-
geting fragments approximately 1.3, 1.8, and 2.4 kb from the capture site. In parallel, for the mutation portions of the assay, 
PCR amplification reactions were conducted with the use of biotinylated primers for specific gene targets. Each of the PCR 
products was then bound to magnetic-bead supports, and a mutation-specific, solid-phase minisequencing protocol was 
used to identify point mutations. BAT-26 deletions (of 4 to 15 bp) were identified according to the size of the reaction prod-
ucts. All minisequencing reaction products were analyzed by capillary electrophoresis with laser-induced fluorescence detec-














Analysis of gene mutations
and BAT-26
Purified DNA
(9 “captures” for K-ras, p53, APC, BAT-26;





Use of “capture” probes
Use of magnetic beads
DNA elution
Use of biotinylated primers
Use of Taq polymerase
PCR amplification
Use of PCR primers
Use of probes
Use of Taq polymerase
Use of  immobilization
of PCR products
Use of sequence-specific primers
Use of labeled nucleotides
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The sample size was predetermined on the basis
of the assumption that the fecal DNA panel and
Hemoccult II had a sensitivity for the detection
of colorectal cancer (i.e., tumor–node–metastasis
[TNM] stage I through IV) of at least 65 percent and
no more than 25 percent, respectively. Given this
assumption, the enrollment of 32 subjects with co-
lorectal cancer would provide the study with a sta-
tistical power of 90 percent to detect a significant
difference at a two-sided alpha level of 0.05 with the




 A post hoc McNemar’s test
was performed to compare the ability of the fecal
DNA panel and Hemoccult II to identify subjects
with fully specified advanced neoplasia (advanced
adenoma or cancer). No interim analyses were per-




A total of 5486 subjects were enrolled, of whom
4404 could be fully evaluated; 1082 (19.7 percent)
could not be evaluated (Fig. 2). The demographic
and clinical characteristics of the population that
could be evaluated and the subgroup that was ana-
lyzed were similar (Table 1).
Colonoscopic findings are shown in Table 2.
Invasive adenocarcinoma was identified in 31 sub-
jects (a prevalence of 0.7 percent). The higher prev-
alence of pathological findings in the analyzed sub-
group reflects the prespecified sampling strategy
for stool processing in subjects with either no pol-
yps or minor polyps. The only clinically significant
complications were four colonoscopic perforations
among 4404 subjects (0.09 percent).
 
fecal dna panel versus hemoccult ii
 
The fecal DNA panel detected 16 of 31 invasive
cancers (TNM stage I, II, or III), for a sensitivity of
51.6 percent; Hemoccult II detected 4 of 31 cancers,
for a sensitivity of 12.9 percent (Table 2). The fecal
DNA panel detected 13 cancers that were missed
by Hemoccult II, whereas Hemoccult II detected
1 cancer that was missed by the panel. This dif-
ference in discordant test results was significant
(P=0.003). In a post hoc analysis among subjects
with node-negative disease (TNM stage I or II), the
sensitivity of the fecal DNA panel was statistically
superior to that of Hemoccult II (56.5 percent vs.
13.0 percent, P=0.006). Among persons with TNM
stage 0, I, II, or III (TNM 0 is carcinoma in situ), the
fecal DNA panel had a sensitivity of 40.8 percent,
whereas Hemoccult II had a sensitivity of 14.1 per-
cent. The fecal DNA panel detected 22 lesions that
were missed by Hemoccult II, whereas Hemoccult
II detected 3 lesions missed by the panel. This dif-
ference in discordant test results was significant
(P<0.001).
Among the 40 subjects who had adenomas
with high-grade dysplasia, the fecal DNA panel de-
tected 13 of the adenomas (32.5 percent), whereas
Hemoccult II detected 6 (15.0 percent). For the de-
tection of other advanced adenomas (villous polyps
and tubular adenomas 1 cm in diameter or larger)
and for minor polyps, the sensitivities of both tests
were consistently less than 20 percent (Table 2).
Among 418 subjects with advanced neoplasia (de-
fined as a tubular adenoma 1 cm in diameter or
larger, a polyp with a villous histologic appearance,
a polyp with high-grade dysplasia, or cancer), the
DNA panel was positive in 76 subjects, whereas
Hemoccult II was positive in 45 subjects (18.2 per-
cent vs. 10.8 percent, P=0.001). There was no sig-
nificant difference in sensitivity according to the
size of the cancer or advanced adenoma for either
test (data not shown).
Among 1423 subjects with negative findings
on colonoscopy, 79 had a positive fecal DNA pan-
el and 68 had a positive Hemoccult II test, for spec-
ificities of 94.4 percent and 95.2 percent, respec-
tively (Table 2). Among subjects with minor polyps,
specificities for the fecal DNA panel and Hemoc-
cult II were 92.4 percent and 95.2 percent, respec-
tively.
Table 3 shows the frequencies of abnormal com-
ponents of the fecal DNA panel as they relate to the
various histologic findings. All components of the
panel contributed to the overall sensitivity of the
test. Although no formal statistical analysis was per-
formed because of the small size of the subgroups,








 were generally greater than those for the
BAT-26 and long-DNA markers for clinically impor-
tant lesions.
We compared a panel of fecal DNA markers and
Hemoccult II as screening tests for colorectal can-
cer in an average-risk, asymptomatic population.
The sensitivity of the fecal DNA panel was four
times that of Hemoccult II for invasive cancer and
more than twice as sensitive for adenomas con-
results
discussion
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
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taining high-grade dysplasia. This increase in sen-
sitivity was achieved without a loss of specificity
among persons with no polyps on colonoscopy. Al-
though this study was not powered to compare
the tests among the different stages of cancer, the
fecal DNA panel appears to be more sensitive than
Hemoccult II for the detection of early (TNM stage
I or II) colorectal cancer. However, since this result
was not prespecified in the analytic plan, it should
be considered preliminary.
The sensitivity of the fecal DNA panel for the de-





 Using a similar panel, Ahl-
quist and colleagues reported a sensitivity of 90





 They used archived stool
specimens from patients with known cancer, many
of whom had advanced disease. The differences
in test characteristics between their study and ours
may be explained by differences in the clinical spec-
trum of disease (e.g., tumor size, tumor stage, or
location within the colon) and study methods.
Tagore et al. used an identical panel of markers to
analyze stool specimens from 52 patients with co-
lorectal cancer and 28 patients with advanced ad-
enomas and reported sensitivities of 64 percent




 Despite the predom-
inance of distal lesions in that study, the test char-
acteristics are closer to those in our study. In other
studies, with the use of different panels of mark-
ers or different techniques, the sensitivity for the





 However, none of these stud-
ies examined asymptomatic persons exclusively.
After we designed our protocol, the detection of
“advanced neoplasia” became a popular outcome





 This term includes more advanced
polyps with respect to size (tubular adenomas 1 cm
in diameter or larger), histologic findings (villous
architecture or high-grade dysplasia), or both fea-
tures, along with invasive cancer. We compared
the sensitivity of the fecal DNA panel with that of
Hemoccult II in a post hoc analysis of the detection
of all cases of advanced colorectal neoplasia, which
included cancers and advanced adenomas. The fecal
DNA panel detected 18.2 percent of samples with
advanced neoplasia, whereas Hemoccult II identi-
fied 10.8 percent. The sensitivity of the DNA panel





 although the confidence intervals
overlap those in other reports. A plausible explana-
tion for this difference in sensitivity is a decrease in
exfoliation of cells owing to smaller adenoma size,
since our subjects had smaller advanced adenomas
than those in other studies (data not shown).
The sensitivity of Hemoccult II — 13 percent
for the detection of cancer — is lower than that re-




 Our finding should
most appropriately be compared with the results
of previous studies in which a reference standard
such as colonoscopy was used in all subjects, irre-
spective of the results of the fecal occult-blood test.
The most relevant study reported a sensitivity for
cancer of 21 percent among 1217 subjects who were
undergoing surveillance colonoscopy after curative
resection of a colorectal neoplasm; these results





Weiss identified 12 of 24 patients with invasive can-




We did not rehydrate the Hemoccult II cards, an





 Our sensitivity results for Hemoccult
II may more closely reflect its sensitivity in clinical
practice; the difference between our results and
those of other reports is potentially important and
deserves further study.
An advantage of using DNA as the analyte is that
a marker panel can be expanded or refined as knowl-
edge about tumor biology evolves. It is worth not-
ing that in our study the sensitivity of the specific
 
Table 1. Characteristics of Subjects Who Could Be 











Mean — yr 68.6 69.5
50–59 yr — no. (%) 570 (12.9) 210 (8.4)
60–69 yr — no. (%) 1971 (44.8) 1150 (45.9)
70–79 yr — no. (%) 1678 (38.1) 1025 (40.9)
≥80 yr — no. (%) 185 (4.2) 122 (4.9)
Male sex — no. (%) 1963(44.6) 1115 (44.5)
Race or ethnic group 
— no. (%)
White 3846 (87.3) 2180 (87.0)
Black 369 (8.4) 217 (8.7)
Other 189 (4.3) 110 (4.4)
Family history of colorectal 
cancer — no. (%)
615 (14.0) 348 (13.9)
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gene-mutation components of the panel for the de-
tection of cancer was similar to that in previous





sensitivity of the long-DNA assay component was
lower than expected, a finding that may be related to
DNA degradation. This first-generation assay panel
has already been improved by enhanced techniques




Our study has certain limitations. First, persons
65 years of age and over were disproportionately
represented in the study population. However, there
is no reason to expect the distribution of DNA ab-
normalities to vary according to age; the observed
sensitivity is likely to apply to younger populations
with a lower prevalence of advanced neoplasia. Sec-
ond, the study was designed as a direct comparison
of two noninvasive screening methods; there were
too few cancers and advanced adenomas with high-
grade dysplasia to provide narrow confidence in-
tervals for the estimated sensitivity of either test.
Third, no inference can be drawn about the ap-
propriate interval for retesting or the effectiveness
of repeated testing with the fecal DNA panel. Fourth,
whereas all DNA analyses of samples were per-
formed in a single laboratory with extensive expe-
rience in the use of the assay, widespread use could
introduce variability that would affect the sensitivi-
ty and specificity.
The place of fecal DNA testing in the current
scheme of colorectal-cancer screening is beyond
the scope of this discussion. The issue requires con-
sideration of the characteristics of the test, risk,
 
* The total in both the group that could be evaluated and the analyzed subgroup includes two subjects who are not included in any other cate-
gory in the table; one had a rectal carcinoid, and one had cloacogenic cancer. The subject with rectal carcinoid was not identified by means of 
either fecal DNA or by fecal occult-blood testing. The subject with cloacogenic cancer was identified by means of fecal DNA testing, but not 
by fecal occult-blood testing. CI denotes confidence interval, and TNM tumor–node–metastasis.
† Stool specimens were selected for DNA testing on the basis of available data (i.e., polyp size and histologic findings) at the time of selection 
for processing. Subsequent audit of data by the clinical research organization resulted in reclassification of less than 5 percent of subjects.
‡ The fecal DNA panel had a specificity of 92.4 percent, and the occult-blood test had a specificity of 95.2 percent (95 percent confidence interval 
for the difference in specificity, ¡5.4 percent to 0.1 percent).
§ The fecal DNA panel had a specificity of 94.4 percent, and the occult-blood test had a specificity of 95.2 percent (95 percent confidence interval 
 
for the difference in specificity, ¡2.4 percent to 0.9 percent).
 
Table 2. Most Advanced Finding at Colonoscopy and Results of the Fecal DNA Panel and Occult-Blood Test in the Analyzed Subgroup.*








(N=2507)† Positive Fecal DNA Panel Positive Occult-Blood Test
 
no. no./total no. % (95% CI) no./total no. % (95% CI)
 
Adenocarcinoma 31 31 16/31 51.6 (34.8–68.0) 4/31 12.9 (5.1–28.9)
TNM stage I 15 15 8/15 53.3 (30.1–75.2) 1/15 6.7 (1.2–29.8)
TNM stage II 8 8 5/8 62.5 (30.6–86.3) 2/8 25.0 (7.1–59.1)
TNM stage III 8 8 3/8  37.5 (13.7–69.4) 1/8 12.5 (2.2–47.1)
TNM stage IV 0 0 0 0
Adenocarcinoma + high-grade 
dysplasia
72 71 29/71  40.8 (30.2–52.5) 10/71  14.1 (7.8–24.6)
Advanced adenoma 426 403 61/403  15.1 (12.0–19.0) 43/403 10.7 (8.0–14.1)
High-grade dysplasia 41 40 13/40 32.5 (20.1–48.0) 6/40 15.0 (7.1–29.1)
Villous adenoma 139 133 24/133 18.0 (12.4–25.4) 13/133 9.8 (5.8–16.0)
Tubular adenoma ≥1 cm 230 214 23/214 10.7 (7.3–15.6) 22/214 10.3 (6.9–15.1)
Unspecified 16 16 1/16 6.2 (1.1–28.3) 2/16  12.5 (3.5–36.0)
Minor polyps‡ 1627 648 49/648 7.6 (5.8–9.9) 31/648 4.8 (3.4–6.7)
Tubular adenoma <1 cm 762 286 23/286 8.0 (5.9–12.7) 15/286 5.2 (3.5–9.2)
Hyperplastic 633 276 17/276 6.2 (3.9–9.6) 10/276 3.6 (2.0–6.5)
Unspecified 232 86 9/86 10.5 (5.6–18.7) 4/86 4.6 (1.8–11.4)
No polyps on colonoscopy§ 2318 1423 79/1423 5.6 (4.5–6.9) 68/1423 4.8 (3.9–5.8)
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cost, interval between tests, acceptability to patients,
and compliance. Although colonoscopy is superior
to other tests in some respects, the Preventive Ser-
vices Task Force has determined that no single test
or strategy for colorectal-cancer screening can be




Several approaches (fecal occult-blood testing, sig-
moidoscopy, colonoscopy, and barium enema ex-





 Despite technical advances
in computed tomographic (“virtual”) colonoscopy,





 The low sensitivity of the fecal DNA panel for
detecting clinically significant neoplasia might
limit its value as a one-time test for cancer, since
it misses most lesions identified on colonoscopy.
However, the use of a less sensitive test at frequent
intervals in a program of screening may be as effec-
tive for the detection of important neoplasia as a





 Further study would be required
to assess this issue. Nonetheless, the availability of
an accurate, noninvasive test might remove one of
the barriers to more widespread screening.
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* BAT-26 is a microsatellite-instability marker.
 
† A marker of long DNA is thought to reflect disordered apoptosis of cancer cells sloughed into the colonic lumen.
 
Table 3. Most Advanced Finding at Colonoscopy and Positivity of Individual Fecal DNA Tests.
Most Advanced Finding 
at Colonoscopy
Total 












Adenocarcinoma 31 16 (51.6) 5 (16.1) 8 (25.8) 9 (29.0) 2 (6.5) 1 (3.2)
Advanced adenoma 403 61 (15.1) 18 (4.5) 11 (2.7) 27 (6.7) 5 (1.2) 8 (2.0)
High-grade dysplasia 40 13 (32.5) 5 (12.5) 2 (5.0) 3 (7.5) 0 5 (12.5)
Other 363 48 (13.2) 13 (3.6) 9 (2.5) 24 (6.6) 5 (1.4) 3 (0.6)
Minor polyps 648 49 (7.6) 19 (2.9) 5 (0.8) 16 (2.5) 4 (0.6) 8 (1.2)
No polyps on colonoscopy 1423 79 (5.6) 22 (1.5) 16 (1.1) 11 (0.8) 16 (1.1) 18 (1.3)
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